AAAAAA
Results:
1-25
|
Results: 25
Authors:
Cocquyt, V
Van Belie, S
Reinhardt, RR
Decramer, MLA
O'Brien, M
Schellens, JHM
Borms, M
Verbeke, L
Van Aelst, F
De Smet, M
Carides, AD
Eldridge, K
Gertz, BJ
Citation: V. Cocquyt et al., Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis, EUR J CANC, 37(7), 2001, pp. 835-842
Authors:
Campos, D
Pereira, JR
Reinhardt, RR
Carracedo, C
Poli, S
Vogel, C
Martinez-Cedillo, J
Erazo, A
Wittreich, J
Eriksson, LO
Carides, AD
Gertz, BJ
Citation: D. Campos et al., Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone, J CL ONCOL, 19(6), 2001, pp. 1759-1767
Authors:
Brater, DC
Harris, C
Redfern, JS
Gertz, BJ
Citation: Dc. Brater et al., Renal effects of COX-2-selective inhibitors, AM J NEPHR, 21(1), 2001, pp. 1-15
Authors:
Schwartz, JI
Agrawal, NGB
Wong, PH
Bachmann, KA
Porras, AG
Miller, JL
Ebel, DL
Sack, MR
Holmes, GB
Redfern, JS
Gertz, BJ
Citation: Ji. Schwartz et al., Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients, J CLIN PHAR, 41(10), 2001, pp. 1120-1130
Authors:
Schwartz, JI
De Smet, M
Larson, PJ
Verbesselt, R
Ebel, DL
Lins, R
Lens, S
Porras, AG
Gertz, BJ
Citation: Ji. Schwartz et al., Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers, J CLIN PHAR, 41(1), 2001, pp. 107-112
Authors:
Murphy, MG
Weiss, S
McClung, M
Schnitzer, T
Cerchio, K
Connor, J
Krupa, D
Gertz, BJ
Citation: Mg. Murphy et al., Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women, J CLIN END, 86(3), 2001, pp. 1116-1125
Authors:
Wight, NJ
Gottesdiener, K
Garlick, NM
Atherton, CT
Novak, S
Gertz, BJ
Calder, NA
Cote, J
Wong, P
Dallob, A
Hawkey, CJ
Citation: Nj. Wight et al., Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production, GASTROENTY, 120(4), 2001, pp. 867-873
Authors:
Codner, E
Cassorla, F
Tiulpakov, AN
Mericq, MV
Avila, A
Pescovitz, OH
Svensson, J
Cerchio, K
Krupa, D
Gertz, BJ
Murphy, G
Citation: E. Codner et al., Effects of oral administration of ibutamoren mesylate, a nonpeptide growthhormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children, CLIN PHARM, 70(1), 2001, pp. 91-98
Authors:
Konstam, MA
Weir, MR
Reicin, A
Shapiro, D
Sperling, RS
Barr, E
Gertz, BJ
Citation: Ma. Konstam et al., Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib, CIRCULATION, 104(19), 2001, pp. 2280-2288
Authors:
Curtis, SP
Eardley, I
Boyce, M
Larson, P
Haesen, R
Gottesdiener, K
Gertz, BJ
Citation: Sp. Curtis et al., Single dose methodology to assess the influence of an alpha(1)-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia, BR J CL PH, 49(3), 2000, pp. 269-273
Authors:
Van Hecken, A
Schwartz, JI
Depre, M
De Lepeleire, I
Dallob, A
Tanaka, W
Wynants, K
Buntinx, A
Arnout, J
Wong, PH
Ebel, DL
Gertz, BJ
De Schepper, PJ
Citation: A. Van Hecken et al., Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers, J CLIN PHAR, 40(10), 2000, pp. 1109-1120
Authors:
Depre, M
Ehrich, E
Van Hecken, A
De Lepeleire, I
Dallob, A
Wong, P
Porras, A
Gertz, BJ
De Schepper, PJ
Citation: M. Depre et al., Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans, EUR J CL PH, 56(2), 2000, pp. 167-174
Authors:
Schwartz, JI
Bugianesi, KJ
Ebel, DL
De Smet, M
Haesen, R
Larson, PJ
Ko, A
Verbesselt, R
Hunt, TL
Lins, R
Lens, S
Porras, AG
Dieck, J
Keymeulen, B
Gertz, BJ
Citation: Ji. Schwartz et al., The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin, CLIN PHARM, 68(6), 2000, pp. 626-636
Authors:
Swan, SK
Rudy, DW
Lasseter, KC
Ryan, CF
Buechel, KL
Lambrecht, LJ
Pinto, MB
Dilzer, SC
Obrda, O
Sundblad, KJ
Gumbs, CP
Ebel, DL
Quan, H
Larson, PJ
Schwartz, JI
Musliner, TA
Gertz, BJ
Brater, DC
Yao, SL
Citation: Sk. Swan et al., Effect of cyclooxygenase-2 inhibition on renal function in elderly personsreceiving a low-salt diet - A randomized, controlled trial, ANN INT MED, 133(1), 2000, pp. 1-9
Authors:
Murphy, MG
Bach, MA
Plotkin, D
Bolognese, J
Ng, J
Krupa, D
Cerchio, K
Gertz, BJ
Citation: Mg. Murphy et al., Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults, J BONE MIN, 14(7), 1999, pp. 1182-1188
Authors:
Ehrich, EW
Schnitzer, TJ
McIlwain, H
Levy, R
Wolfe, F
Weisman, M
Zeng, Q
Morrison, B
Bolognese, J
Seidenberg, B
Gertz, BJ
Citation: Ew. Ehrich et al., Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib, J RHEUMATOL, 26(11), 1999, pp. 2438-2447
Authors:
Porras, AG
Holland, SD
Gertz, BJ
Citation: Ag. Porras et al., Pharmacokinetics of alendronate, CLIN PHARMA, 36(5), 1999, pp. 315-328
Authors:
Newby, DE
Sciberras, DG
Ferro, CJ
Gertz, BJ
Sommerville, D
Majumdar, A
Lowry, RC
Webb, DJ
Citation: De. Newby et al., Substance P-induced vasodilatation is mediated by the neurokinin type I receptor but does not contribute to basal vascular tone in man, BR J CL PH, 48(3), 1999, pp. 336-344
Authors:
Knorr, B
Larson, P
Nguyen, HH
Holland, S
Reiss, TF
Chervinsky, P
Blake, K
van Nispen, CHM
Noonan, G
Freeman, A
Haesen, R
Michiels, N
Rogers, JD
Amin, RD
Zhao, J
Xu, X
Seidenberg, BC
Gertz, BJ
Spielberg, S
Citation: B. Knorr et al., Montelukast dose selection in 6-to 14-year-olds: Comparison of single-dosepharmacokinetics in children and adults, J CLIN PHAR, 39(8), 1999, pp. 786-793
Authors:
Cocquyt, V
Kline, WF
Gertz, BJ
Van Belle, SJP
Holland, SD
DeSmet, M
Quan, H
Vyas, KP
Zhang, KYE
De Greve, J
Porras, AG
Citation: V. Cocquyt et al., Pharmacokinetics of intravenous alendronate, J CLIN PHAR, 39(4), 1999, pp. 385-393
Authors:
McCrea, J
Prueksaritanont, T
Gertz, BJ
Carides, A
Gillen, L
Antonello, S
Brucker, MJ
Miller-Stein, C
Osborne, B
Waldman, S
Citation: J. Mccrea et al., Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity, J CLIN PHAR, 39(12), 1999, pp. 1212-1220
Authors:
Navari, RM
Reinhardt, RR
Gralla, RJ
Kris, MG
Hesketh, PJ
Khojasteh, A
Kindler, H
Grote, TH
Pendergrass, K
Grunberg, SM
Carides, AD
Gertz, BJ
Citation: Rm. Navari et al., Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptorantagonist, N ENG J MED, 340(3), 1999, pp. 190-195
Authors:
Catella-Lawson, F
McAdam, B
Morrison, BW
Kapoor, S
Kujubu, D
Antes, L
Lasseter, KC
Quan, H
Gertz, BJ
Fitzgerald, GA
Citation: F. Catella-lawson et al., Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J PHARM EXP, 289(2), 1999, pp. 735-741
Authors:
Schwartz, JI
Chan, CC
Mukhopadhyay, S
McBride, KJ
Jones, TM
Adcock, S
Moritz, C
Hedges, J
Grasing, K
Dobratz, D
Cohen, RA
Davidson, MH
Bachmann, KA
Gertz, BJ
Citation: Ji. Schwartz et al., Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans, CLIN PHARM, 65(6), 1999, pp. 653-660
Authors:
Ehrich, EW
Dallob, A
De Lepeleire, I
Van Hecken, A
Riendeau, D
Yuan, WY
Porras, A
Wittreich, J
Seibold, JR
De Schepper, P
Mehlisch, DR
Gertz, BJ
Citation: Ew. Ehrich et al., Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model, CLIN PHARM, 65(3), 1999, pp. 336-347
Risultati:
1-25
|